The Claim
Bimagrumab increases lean mass during weight loss, while apitegromab reduces the rate of lean mass loss during weight loss.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
During weight loss, bimagrumab leads to an increase in lean mass, while apitegromab slows the loss of lean mass.
See the scientific wording
Bimagrumab increases lean mass during weight loss, while apitegromab only reduces the rate of lean mass loss.
A drug that blocks myostatin or activin signals tells muscle cells to build more protein and stop breaking down, so muscle mass stays the same or grows even when the body is losing weight. At the same time, fat tissue breaks down more because the same signals that suppress muscle also suppress fat burning, so blocking them helps the body burn fat without losing muscle.
What the research says
3 studiesBimagrumab helped people keep their muscle while losing weight, unlike other treatments that caused more muscle loss. But this study didn't test apitegromab, so we can't say how it compares.
The study shows that apitegromab helps people keep more muscle while losing weight, which matches part of the claim. It doesn't test bimagrumab, so we can't say for sure about that drug, but what it does show supports the part about apitegromab.
Study: Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
The study shows that bimagrumab helps people gain muscle while losing weight, which matches part of the claim. But it doesn't say anything about apitegromab, so we can't confirm that part.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 3 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.